Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ImClone Systems
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
ImClone's lead program Erbitux (cetuximab) is FDA approved for metastatic colorectal cancer and head and neck cancer; their pipeline included follow-on antibodies (e.g., IMC-11F8, later called necitumumab) and other biologics, some of which reached late clinical (Phase II/III) or commercial stages[2][3][6][7].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Bristol Myers Squibb (co-marketing Erbitux in North America, shared R&D)Merck KGaA (co-development/marketing Erbitux in Japan and Europe)
Beyond the preview
Go deeper on ImClone Systems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImClone Systems.